sermaglutide peptide apis online manufacturer Manufacturer

Sermaglutide CAS 910463-68-2 Molecular Weight 4113.64 On September 20, 2019, the FDA officially approved the marketing application for Sommarutide, which is used in combination with diet and exercise to improve blood sugar control in patients with type 2 diabetes. Sommarutide is a human GLP-1 analogue with high albumin affinity and a long half-life. It can be administered once a week to stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner.